Wealth Alliance Advisory Group LLC Cuts Stock Position in GSK plc (NYSE:GSK)

Wealth Alliance Advisory Group LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 2.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,575 shares of the pharmaceutical company’s stock after selling 292 shares during the period. Wealth Alliance Advisory Group LLC’s holdings in GSK were worth $484,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. 1832 Asset Management L.P. raised its position in shares of GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after acquiring an additional 257 shares in the last quarter. Personal CFO Solutions LLC raised its holdings in shares of GSK by 2.7% during the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after purchasing an additional 263 shares during the period. Boltwood Capital Management lifted its position in shares of GSK by 2.5% in the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares during the last quarter. J.W. Cole Advisors Inc. boosted its holdings in shares of GSK by 4.7% in the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after buying an additional 271 shares during the period. Finally, First Affirmative Financial Network grew its position in shares of GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after buying an additional 283 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. The Goldman Sachs Group started coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $50.00.

GSK Trading Up 0.4 %

GSK stock opened at $43.91 on Friday. The firm has a 50 day simple moving average of $40.11 and a 200-day simple moving average of $41.58. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The stock has a market capitalization of $91.00 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be given a dividend of $0.3843 per share. The ex-dividend date of this dividend is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.50%. GSK’s payout ratio is 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.